BeOne Medicines (ONC) Accumulated Expenses (2015 - 2026)

BeOne Medicines (ONC) has 12 years of Accumulated Expenses data on file, last reported at $1.1 billion in Q1 2026.

• Quarterly Accumulated Expenses rose 55.93% year-over-year to $1.1 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 billion (up 55.93% YoY) and the FY2025 annual result came in at $1.1 billion, up 38.0% from the prior year.
• Accumulated Expenses slipped to $1.1 billion in Q1 2026 per ONC's latest filing, from $1.1 billion in the prior quarter.
• Across five years, Accumulated Expenses topped out at $1.1 billion in Q4 2025 and bottomed at $386.0 million in Q1 2022.
• The 5-year median for Accumulated Expenses is $646.5 million (2024), against an average of $674.7 million.
• The widest annual swing landed in 2023, when Accumulated Expenses grew 0.17%; it then surged 55.93% in 2026.
• Tracing ONC's Accumulated Expenses over 5 years: stood at $619.5 million in 2022, then grew by 11.99% to $693.7 million in 2023, then advanced by 15.85% to $803.7 million in 2024, then jumped by 38.0% to $1.1 billion in 2025, then dropped by 2.69% to $1.1 billion in 2026.
• Per Business Quant, the three latest ONC Accumulated Expenses figures stand at $1.1 billion (Q1 2026), $1.1 billion (Q4 2025), and $1.0 billion (Q3 2025).

Peer Comparison